

Samantha C Burnham

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9481935/publications.pdf>

Version: 2024-02-01

65
papers

4,712
citations

218381

26
h-index

118652

62
g-index

68
all docs

68
docs citations

68
times ranked

7142
citing authors

#	ARTICLE	IF	CITATIONS
1	Alzheimer's disease research progress in Australia: The Alzheimer's Association International Conference Satellite Symposium in Sydney. <i>Alzheimer's and Dementia</i> , 2022, 18, 178-190.	0.4	5
2	Mesial temporal tau in amyloid- β -negative cognitively normal older persons. <i>Alzheimer's Research and Therapy</i> , 2022, 14, 51.	3.0	12
3	Characteristics of subjective cognitive decline associated with amyloid positivity. <i>Alzheimer's and Dementia</i> , 2022, 18, 1832-1845.	0.4	22
4	Visually Identified Tau 18F-MK6240 PET Patterns in Symptomatic Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2022, , 1-11.	1.2	7
5	Association of β -Amyloid Level, Clinical Progression, and Longitudinal Cognitive Change in Normal Older Individuals. <i>Neurology</i> , 2021, 96, e662-e670.	1.5	34
6	Aggregation of Abnormal Memory Scores and Risk of Incident Alzheimer's Disease Dementia: A Measure of Objective Memory Impairment in Amnesic Mild Cognitive Impairment. <i>Journal of the International Neuropsychological Society</i> , 2021, 27, 146-157.	1.2	3
7	Mesial temporal tau is related to worse cognitive performance and greater neocortical tau load in amyloid- β -negative cognitively normal individuals. <i>Neurobiology of Aging</i> , 2021, 97, 41-48.	1.5	23
8	SPON1 Is Associated with Amyloid- β and APOE ϵ 4-Related Cognitive Decline in Cognitively Normal Adults. <i>Journal of Alzheimer's Disease Reports</i> , 2021, 5, 111-120.	1.2	5
9	Fifteen Years of the Australian Imaging, Biomarkers and Lifestyle (AIBL) Study: Progress and Observations from 2,359 Older Adults Spanning the Spectrum from Cognitive Normality to Alzheimer's Disease. <i>Journal of Alzheimer's Disease Reports</i> , 2021, 5, 443-468.	1.2	59
10	Relationship between amyloid and tau levels and its impact on tau spreading. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2225-2232.	3.3	30
11	β Imaging in Aging, Alzheimer's Disease, and Other Neurodegenerative Conditions. , 2021, , 283-343.		0
12	Connecting Cohorts to Diminish Alzheimer's Disease (CONCORD-AD): A Report of an International Research Collaboration Network. <i>Journal of Alzheimer's Disease</i> , 2021, , 1-15.	1.2	1
13	Structural core of the executive control network: A high angular resolution diffusion MRI study. <i>Human Brain Mapping</i> , 2020, 41, 1226-1236.	1.9	40
14	Longitudinal evaluation of the natural history of amyloid- β in plasma and brain. <i>Brain Communications</i> , 2020, 2, fcaa041.	1.5	21
15	Impact of APOE- ϵ 4 carriage on the onset and rates of neocortical β -amyloid deposition. <i>Neurobiology of Aging</i> , 2020, 95, 46-55.	1.5	32
16	Elecsys CSF biomarker immunoassays demonstrate concordance with amyloid-PET imaging. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 36.	3.0	39
17	Diminished Learning Over Repeated Exposures (LORE) in preclinical Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12132.	1.2	19
18	Effect of Pupil Dilation with Tropicamide on Retinal Vascular Caliber. <i>Ophthalmic Epidemiology</i> , 2019, 26, 400-407.	0.8	10

#	ARTICLE	IF	CITATIONS
19	The dawn of robust individualised risk models for dementia. <i>Lancet Neurology</i> , The, 2019, 18, 985-987.	4.9	6
20	APPLICATION OF THE NIA-AA RESEARCH FRAMEWORK: TOWARDS A BIOLOGICAL DEFINITION OF ALZHEIMER'S DISEASE USING CEREBROSPINAL FLUID BIOMARKERS IN THE AIBL STUDY. <i>Journal of prevention of Alzheimer's disease</i> , The, 2019, 6, 1-8.	1.5	20
21	Using subjective cognitive decline to identify high global amyloid in community-based samples: A cross-cohort study. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 670-678.	1.2	19
22	Klotho allele status is not associated with A β 2 and APOE ϵ 4-related cognitive decline in preclinical Alzheimer's disease. <i>Neurobiology of Aging</i> , 2019, 76, 162-165.	1.5	23
23	The trinity of tau, trauma, and time. <i>Lancet Neurology</i> , The, 2019, 18, 715-717.	4.9	0
24	COMT val158met is not associated with A β 2-amyloid and APOE ϵ 4 related cognitive decline in cognitively normal older adults. <i>IBRO Reports</i> , 2019, 6, 147-152.	0.3	5
25	Blood-based molecular biomarkers for Alzheimer's disease. <i>Molecular Brain</i> , 2019, 12, 26.	1.3	180
26	Subjective memory complaints predict baseline but not future cognitive function over three years: results from the Western Australia Memory Study. <i>International Psychogeriatrics</i> , 2019, 31, 513-525.	0.6	13
27	Identification of Functional Connectivity Features in Depression Subtypes Using a Data-Driven Approach. <i>Lecture Notes in Computer Science</i> , 2019, , 96-103.	1.0	0
28	Cognitive gene risk profile for the prediction of cognitive decline in presymptomatic Alzheimer's disease. <i>Personalized Medicine in Psychiatry</i> , 2018, 7-8, 14-20.	0.1	13
29	Associations of Dietary Protein and Fiber Intake with Brain and Blood Amyloid- β 2. <i>Journal of Alzheimer's Disease</i> , 2018, 61, 1589-1598.	1.2	44
30	Imaging tau and amyloid- β 2 proteinopathies in Alzheimer disease and other conditions. <i>Nature Reviews Neurology</i> , 2018, 14, 225-236.	4.9	321
31	KIBRA is associated with accelerated cognitive decline and hippocampal atrophy in APOE ϵ 4-positive cognitively normal adults with high A β 2-amyloid burden. <i>Scientific Reports</i> , 2018, 8, 2034.	1.6	31
32	Association of β 2-Amyloid and Apolipoprotein E ϵ 4 With Memory Decline in Preclinical Alzheimer Disease. <i>JAMA Neurology</i> , 2018, 75, 488.	4.5	70
33	Alzheimer's Disease: A Journey from Amyloid Peptides and Oxidative Stress, to Biomarker Technologies and Disease Prevention Strategies—Gains from AIBL and DIAN Cohort Studies. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 965-992.	1.2	96
34	Baseline Amnesic Severity Predicts Progression From Amnesic Mild Cognitive Impairment to Alzheimer Disease Dementia at 3 Years. <i>Alzheimer Disease and Associated Disorders</i> , 2018, 32, 190-196.	0.6	19
35	Utility of an Alzheimer's Disease Risk-Weighted Polygenic Risk Score for Predicting Rates of Cognitive Decline in Preclinical Alzheimer's Disease: A Prospective Longitudinal Study. <i>Journal of Alzheimer's Disease</i> , 2018, 66, 1193-1211.	1.2	27
36	A Polygenic Risk Score Derived From Episodic Memory Weighted Genetic Variants Is Associated With Cognitive Decline in Preclinical Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 423.	1.7	16

#	ARTICLE	IF	CITATIONS
37	Examining Relationships among Subjective Cognitive Concerns and Positive and Negative Affect in Cognitively Normal Older Adults Using a Weekly, Internet-Based Method: A Pilot Study. <i>American Journal of Geriatric Psychiatry</i> , 2018, 26, S95-S96.	0.6	1
38	Sex, amyloid, and <i>APOE</i> ϵ 4 and risk of cognitive decline in preclinical Alzheimer's disease: Findings from three well-characterized cohorts. <i>Alzheimer's and Dementia</i> , 2018, 14, 1193-1203.	0.4	169
39	Self-Reported Physical Activity is Associated with Tau Burden Measured by Positron Emission Tomography. <i>Journal of Alzheimer's Disease</i> , 2018, 63, 1299-1305.	1.2	28
40	Constructing longitudinal disease progression curves using sparse, short-term individual data with an application to Alzheimer's disease. <i>Statistics in Medicine</i> , 2017, 36, 2720-2734.	0.8	20
41	Increased Carbohydrate Intake is Associated with Poorer Performance in Verbal Memory and Attention in an <i>APOE</i> Genotype-Dependent Manner. <i>Journal of Alzheimer's Disease</i> , 2017, 58, 193-201.	1.2	12
42	Insulin resistance is associated with reductions in specific cognitive domains and increases in CSF tau in cognitively normal adults. <i>Scientific Reports</i> , 2017, 7, 9766.	1.6	59
43	$A\beta$ -amyloid and Tau Imaging in Dementia. <i>Seminars in Nuclear Medicine</i> , 2017, 47, 75-88.	2.5	96
44	[P4464]: THE IMPACT OF <i>APOE</i> ϵ 4 CARRIAGE ON $A\beta$ AMYLOID DEPOSITION IN AIBL. <i>Alzheimer's and Dementia</i> , 2017, 13, P1510.	0.4	0
45	[P4465]: IMPLEMENTING THE ATN CLASSIFICATION IN AIBL. <i>Alzheimer's and Dementia</i> , 2017, 13, P1511.	0.4	1
46	COMPUTERIZED COGNITIVE TESTING FOR USE IN CLINICAL TRIALS: A COMPARISON OF THE NIH TOOLBOX AND COGSTATE C3 BATTERIES. <i>Journal of Prevention of Alzheimer's Disease</i> , The, 2017, 4, 1-9.	1.5	46
47	Predicting Alzheimer disease from a blood-based biomarker profile. <i>Neurology</i> , 2016, 87, 1093-1101.	1.5	26
48	Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer's disease pathophysiology (SNAP) or Alzheimer's disease pathology: a longitudinal study. <i>Lancet Neurology</i> , The, 2016, 15, 1044-1053.	4.9	175
49	THE FEASIBILITY OF AT-HOME IPAD COGNITIVE TESTING FOR USE IN CLINICAL TRIALS. <i>Journal of Prevention of Alzheimer's Disease</i> , The, 2016, 3, 1-5.	1.5	39
50	Novel Statistically-Derived Composite Measures for Assessing the Efficacy of Disease-Modifying Therapies in Prodromal Alzheimer's Disease Trials: An AIBL Study. <i>Journal of Alzheimer's Disease</i> , 2015, 46, 1079-1089.	1.2	28
51	Blood Protein Markers of Neocortical Amyloid- β Burden: A Candidate Study Using SOMAscan Technology. <i>Journal of Alzheimer's Disease</i> , 2015, 46, 947-961.	1.2	49
52	Follow-up plasma apolipoprotein E levels in the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing (AIBL) cohort. <i>Alzheimer's Research and Therapy</i> , 2015, 7, 16.	3.0	22
53	The relationship between subacromial bursa thickness on ultrasound and shoulder pain in open water endurance swimmers over time. <i>Journal of Science and Medicine in Sport</i> , 2015, 18, 373-377.	0.6	15
54	Decreased serum zinc is an effect of ageing and not Alzheimer's disease. <i>Metallomics</i> , 2014, 6, 1216-1219.	1.0	34

#	ARTICLE	IF	CITATIONS
55	Influence of <i>BDNF</i> Val66Met on the relationship between physical activity and brain volume. <i>Neurology</i> , 2014, 83, 1345-1352.	1.5	58
56	A blood-based predictor for neocortical A β burden in Alzheimer's disease: results from the AIBL study. <i>Molecular Psychiatry</i> , 2014, 19, 519-526.	4.1	108
57	Plasma Amyloid- β Levels are Significantly Associated with a Transition Toward Alzheimer's Disease as Measured by Cognitive Decline and Change in Neocortical Amyloid Burden. <i>Journal of Alzheimer's Disease</i> , 2014, 40, 95-104.	1.2	41
58	P4-293: COMPARISON OF THREE NORMATIVE DATA CORRECTION APPROACHES: A CROSS-SECTIONAL EVALUATION IN THE AIBL STUDY. , 2014, 10, P891-P892.		2
59	Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. <i>Lancet Neurology</i> , The, 2013, 12, 357-367.	4.9	1,738
60	Physical activity and amyloid- β plasma and brain levels: results from the Australian Imaging, Biomarkers and Lifestyle Study of Ageing. <i>Molecular Psychiatry</i> , 2013, 18, 875-881.	4.1	185
61	Intense physical activity is associated with cognitive performance in the elderly. <i>Translational Psychiatry</i> , 2012, 2, e191-e191.	2.4	93
62	Blood-Based Protein Biomarkers for Diagnosis of Alzheimer Disease. <i>Archives of Neurology</i> , 2012, 69, 1318.	4.9	348
63	Determining Reaction Networks. <i>Computer Aided Chemical Engineering</i> , 2009, 27, 561-566.	0.3	2
64	Inference of chemical reaction networks. <i>Chemical Engineering Science</i> , 2008, 63, 862-873.	1.9	20
65	IDENTIFYING CHEMICAL REACTION NETWORK MODELS. <i>IFAC Postprint Volumes IPPV / International Federation of Automatic Control</i> , 2007, 40, 225-230.	0.4	2